Institute for Clinical and Economic Review (ICER)
@icer-review.bsky.social
Encouraging fair pricing, fair access, and future innovation within the US health care system | Reposts not endorsements
This week ICER marks the 5-year anniversary of ICER Analytics™, our cloud-based platform that has revolutionized the ability of users to develop formularies, negotiate drug prices, and explore new ways to apply ICER’s evidence. Learn more at analytics.icer.org.
November 21, 2025 at 4:30 PM
This week ICER marks the 5-year anniversary of ICER Analytics™, our cloud-based platform that has revolutionized the ability of users to develop formularies, negotiate drug prices, and explore new ways to apply ICER’s evidence. Learn more at analytics.icer.org.
ICER #WeeklyView: ICER Analytics is 5, ICER interviewed on GLP-1 pricing, & health benefits costs to increase conta.cc/4ieQnKC
ICER Weekly View: ICER Analytics is 5, ICER interviewed on GLP-1 pricing, & health benefits costs to increase
Email from Institute for Clinical and Economic Review ICER Weekly View View as Webpage Sign up for ICER's Weekly View Newsletter Weekly View November 21, 2025 From the desk of ICER Communications (P
conta.cc
November 21, 2025 at 12:06 PM
ICER #WeeklyView: ICER Analytics is 5, ICER interviewed on GLP-1 pricing, & health benefits costs to increase conta.cc/4ieQnKC
ICER #WeeklyView: This holiday season, consider donating to ICER conta.cc/4oMsVXK
ICER Weekly View: This holiday season, consider donating to ICER
Email from Institute for Clinical and Economic Review ICER Weekly View View as Webpage Sign up for ICER's Weekly View Newsletter Weekly View November 14, 2025 From the desk of ICER Communications Go
conta.cc
November 14, 2025 at 1:07 PM
ICER #WeeklyView: This holiday season, consider donating to ICER conta.cc/4oMsVXK
Institute for Clinical and Economic Review Releases Draft Scope on Vaccines for Covid-19: tinyurl.com/4enrmhsf
Institute for Clinical and Economic Review Releases Draft Scope on Vaccines for Covid-19 - ICER
Report will be subject of New England CEPAC meeting in June 2026; Draft Scoping Document open to public comment until December 2, 2025.
tinyurl.com
November 10, 2025 at 1:15 PM
Institute for Clinical and Economic Review Releases Draft Scope on Vaccines for Covid-19: tinyurl.com/4enrmhsf
ICER #WeeklyView: Obesity public meeting, paying for value for obesity meds, & responses to ICER’s Launch Price and Access Report conta.cc/4nLPYAy
ICER Weekly View: Obesity public meeting, paying for value for obesity meds, & responses to ICER’s Launch Price and Access Report
Email from Institute for Clinical and Economic Review ICER Weekly View View as Webpage Sign up for ICER's Weekly View Newsletter Weekly View November 7, 2025 From the desk of ICER Communications Goo
conta.cc
November 7, 2025 at 12:25 PM
ICER #WeeklyView: Obesity public meeting, paying for value for obesity meds, & responses to ICER’s Launch Price and Access Report conta.cc/4nLPYAy
ICER #WeeklyView: NCFB and obesity Evidence Reports, Cigna ends rebates, & updated approval for biosimilars conta.cc/4oIRkg6
ICER Weekly View: NCFB and obesity Evidence Reports, Cigna ends rebates, & updated approval for biosimilars
Email from Institute for Clinical and Economic Review ICER Weekly View View as Webpage Sign up for ICER's Weekly View Newsletter Weekly View October 31, 2025 From the desk of ICER Communications Hap
conta.cc
October 31, 2025 at 11:05 AM
ICER #WeeklyView: NCFB and obesity Evidence Reports, Cigna ends rebates, & updated approval for biosimilars conta.cc/4oIRkg6
Institute for Clinical and Economic Review Publishes Final Evidence Report on Treatment for Non-Cystic Fibrosis Bronchiectasis: tinyurl.com/4rmnz269
Institute for Clinical and Economic Review Publishes Final Evidence Report on Treatment for Non-Cystic Fibrosis Bronchiectasis - ICER
Independent appraisal committee voted unanimously on the positive net health benefit of brensocatib; but current pricing represents “low” value for money.
tinyurl.com
October 30, 2025 at 12:04 PM
Institute for Clinical and Economic Review Publishes Final Evidence Report on Treatment for Non-Cystic Fibrosis Bronchiectasis: tinyurl.com/4rmnz269
Institute for Clinical and Economic Review Publishes Evidence Report on Treatments for Obesity: tinyurl.com/3wbemnr9
Institute for Clinical and Economic Review Publishes Evidence Report on Treatments for Obesity - ICER
All three drugs result in substantial weight loss; the therapies are cost-effective, but the very large population appropriate for treatment creates important budgetary issues.
tinyurl.com
October 29, 2025 at 12:09 PM
Institute for Clinical and Economic Review Publishes Evidence Report on Treatments for Obesity: tinyurl.com/3wbemnr9
Today: Join ICER for a conversation around rising launch prices, and the implications for affordability and patient access. Register for the 2025 Launch Price and Access Report: Policy Implications webinar: tinyurl.com/3xukfka2
2025 Launch Price and Access Report: Policy Implications
tinyurl.com
October 27, 2025 at 1:27 PM
Today: Join ICER for a conversation around rising launch prices, and the implications for affordability and patient access. Register for the 2025 Launch Price and Access Report: Policy Implications webinar: tinyurl.com/3xukfka2
ICER #WeeklyView: Launch Price and Access Report and webinar, & assessments for narcolepsy and smoking cessation conta.cc/4nhUsP2
ICER Weekly View: Launch Price and Access Report and webinar, & assessments for narcolepsy and smoking cessation
Email from Institute for Clinical and Economic Review ICER Weekly View View as Webpage Sign up for ICER's Weekly View Newsletter Weekly View October 24, 2025 From the desk of ICER Communications Goo
conta.cc
October 24, 2025 at 12:25 PM
ICER #WeeklyView: Launch Price and Access Report and webinar, & assessments for narcolepsy and smoking cessation conta.cc/4nhUsP2
New Institute for Clinical and Economic Review Report Shows Significant Jump in Launch Prices, Exceeding Inflation and GDP Growth: tinyurl.com/46swvktj
New Institute for Clinical and Economic Review Report Shows Significant Jump in Launch Prices, Exceeding Inflation and GDP Growth - ICER
Nearly $1.5 billion could have been saved in one year alone if prices matched ICER value estimates; Patient access often hindered by delayed insurance coverage policies
tinyurl.com
October 23, 2025 at 12:23 PM
New Institute for Clinical and Economic Review Report Shows Significant Jump in Launch Prices, Exceeding Inflation and GDP Growth: tinyurl.com/46swvktj
Institute for Clinical and Economic Review Releases Draft Evidence Report on Treatment for Smoking Cessation: tinyurl.com/3c9n6bkh
Institute for Clinical and Economic Review Releases Draft Evidence Report on Treatment for Smoking Cessation - ICER
Public comment period now open until November 17, 2025; Requests to make oral comment during public meeting also being accepted.
tinyurl.com
October 20, 2025 at 8:19 PM
Institute for Clinical and Economic Review Releases Draft Evidence Report on Treatment for Smoking Cessation: tinyurl.com/3c9n6bkh
Institute for Clinical and Economic Review to Assess Treatment for Narcolepsy: tinyurl.com/2vw57seu
Institute for Clinical and Economic Review to Assess Treatment for Narcolepsy - ICER
Report will be subject of Midwest CEPAC meeting in May 2026; Draft Scoping Document open to public comment until November 5, 2025
tinyurl.com
October 17, 2025 at 12:27 PM
Institute for Clinical and Economic Review to Assess Treatment for Narcolepsy: tinyurl.com/2vw57seu
ICER #WeeklyView: Launch Price and Access Report webinar, On Point interview, & California PBM reforms conta.cc/47fZHsJ
ICER Weekly View: Launch Price and Access Report webinar, On Point interview, & California PBM reforms
Email from Institute for Clinical and Economic Review ICER Weekly View View as Webpage Sign up for ICER's Weekly View Newsletter Weekly View October 17, 2025 From the desk of ICER Communications Goo
conta.cc
October 17, 2025 at 11:14 AM
ICER #WeeklyView: Launch Price and Access Report webinar, On Point interview, & California PBM reforms conta.cc/47fZHsJ
ICER #WeeklyView: HEMA Draft Report, ICER’s paper in Health Affairs Scholar, & the Colorado PDAP vote conta.cc/3KIpfXJ
ICER Weekly View: HEMA Draft Report, ICER’s paper in Health Affairs Scholar, & the Colorado PDAP vote
Email from Institute for Clinical and Economic Review ICER Weekly View View as Webpage Sign up for ICER's Weekly View Newsletter Weekly View October 10, 2025 From the desk of ICER Communications Goo
conta.cc
October 10, 2025 at 11:07 AM
ICER #WeeklyView: HEMA Draft Report, ICER’s paper in Health Affairs Scholar, & the Colorado PDAP vote conta.cc/3KIpfXJ
Health Economics Methods Advisory Group Releases Draft Report: Assessing Treatment Benefits in HTA Decision-Making tinyurl.com/yc47dejv
Health Economics Methods Advisory Group Releases Draft Report: Assessing Treatment Benefits in HTA Decision-Making – Health Economics Methods Advisory
tinyurl.com
October 9, 2025 at 12:06 PM
Health Economics Methods Advisory Group Releases Draft Report: Assessing Treatment Benefits in HTA Decision-Making tinyurl.com/yc47dejv
How to make one line in the FDA Commissioner’s new drug review program into a force for affordable access for patients -- a new Health Affairs Scholar paper by ICER President and CEO Sarah Emond and Chief Scientific Officer Dan Ollendorf: tinyurl.com/32bexcd9
How to make one line in the FDA Commissioner's new drug review program into a force for affordable access for patients
Abstract. The FDA Commissioner's new National Priority Voucher program seeks to accelerate drug approvals for products meeting certain criteria. Interestin
tinyurl.com
October 6, 2025 at 5:26 PM
How to make one line in the FDA Commissioner’s new drug review program into a force for affordable access for patients -- a new Health Affairs Scholar paper by ICER President and CEO Sarah Emond and Chief Scientific Officer Dan Ollendorf: tinyurl.com/32bexcd9
ICER #WeeklyView: Vaccines for COVID-19 to be assessed, Trump Administration’s drug pricing announcements, & ACA subsidies conta.cc/4nCjZDy
ICER Weekly View: Vaccines for COVID-19 to be assessed, Trump Administration’s drug pricing announcements, & ACA subsidies
Email from Institute for Clinical and Economic Review ICER Weekly View View as Webpage Sign up for ICER's Weekly View Newsletter Weekly View October 3, 2025 From the desk of ICER Communications Good
conta.cc
October 3, 2025 at 11:10 AM
ICER #WeeklyView: Vaccines for COVID-19 to be assessed, Trump Administration’s drug pricing announcements, & ACA subsidies conta.cc/4nCjZDy
Institute for Clinical and Economic Review to Assess Vaccines for COVID-19: tinyurl.com/2tfn5pme
Institute for Clinical and Economic Review to Assess Vaccines for COVID-19 - ICER
Report will be subject of New England CEPAC meeting in June 2026.
tinyurl.com
September 29, 2025 at 8:31 PM
Institute for Clinical and Economic Review to Assess Vaccines for COVID-19: tinyurl.com/2tfn5pme
ICER #WeeklyView: NCFB public meeting, GLP-1s lower costs, & pharma responses to new regulations conta.cc/3IIbHe7
ICER Weekly View: NCFB public meeting, GLP-1s lower costs, & pharma responses to new regulations
Email from Institute for Clinical and Economic Review ICER Weekly View View as Webpage Sign up for ICER's Weekly View Newsletter Weekly View September 26, 2025 From the desk of ICER Communications G
conta.cc
September 26, 2025 at 11:08 AM
ICER #WeeklyView: NCFB public meeting, GLP-1s lower costs, & pharma responses to new regulations conta.cc/3IIbHe7
ICER #WeeklyView: CMS report, GLP-1 cost-effectiveness, & soaring health care costs conta.cc/4mjUh59
ICER Weekly View: CMS report, GLP-1 cost-effectiveness, & soaring health care costs
Email from Institute for Clinical and Economic Review ICER Weekly View View as Webpage Sign up for ICER's Weekly View Newsletter Weekly View September 19, 2025 From the desk of ICER Communications G
conta.cc
September 19, 2025 at 11:12 AM
ICER #WeeklyView: CMS report, GLP-1 cost-effectiveness, & soaring health care costs conta.cc/4mjUh59
Institute for Clinical and Economic Review to Undertake Special Report on Crohn’s Disease and Ulcerative Colitis for CMS as Part of Public Comment Process on Medicare Drug Price Negotiations: tinyurl.com/4urn4xf7
Institute for Clinical and Economic Review to Undertake Special Report on Crohn’s Disease and Ulcerative Colitis for CMS as Part of Public Comment Process on Medicare Drug Price Negotiations - ICER
Report to reflect legislative specifications in the Inflation Reduction Act and most recent CMS guidance regarding price negotiations.
tinyurl.com
September 15, 2025 at 12:16 PM
Institute for Clinical and Economic Review to Undertake Special Report on Crohn’s Disease and Ulcerative Colitis for CMS as Part of Public Comment Process on Medicare Drug Price Negotiations: tinyurl.com/4urn4xf7
ICER #WeeklyView: Obesity draft evidence report, NCFB evidence report, & a crackdown on pharma ads conta.cc/46wGALw
ICER Weekly View: Obesity draft evidence report, NCFB evidence report, & a crackdown on pharma ads
Email from Institute for Clinical and Economic Review ICER Weekly View View as Webpage Sign up for ICER's Weekly View Newsletter Weekly View September 12, 2025 From the desk of ICER Communications G
conta.cc
September 12, 2025 at 12:30 PM
ICER #WeeklyView: Obesity draft evidence report, NCFB evidence report, & a crackdown on pharma ads conta.cc/46wGALw
Institute for Clinical and Economic Review Releases Draft Evidence Report on Treatments for Obesity: tinyurl.com/4zzsd7dw
Institute for Clinical and Economic Review Releases Draft Evidence Report on Treatments for Obesity - ICER
Public comment period now open until October 6, 2025; Requests to make oral comment during public meeting also being accepted.
tinyurl.com
September 9, 2025 at 12:09 PM
Institute for Clinical and Economic Review Releases Draft Evidence Report on Treatments for Obesity: tinyurl.com/4zzsd7dw
Institute for Clinical and Economic Review Publishes Evidence Report on Treatment for Non-Cystic Fibrosis Bronchiectasis: tinyurl.com/39by2hs5
Institute for Clinical and Economic Review Publishes Evidence Report on Treatment for Non-Cystic Fibrosis Bronchiectasis - ICER
There are significant uncertainties regarding long term efficacy of brensocatib; ICER estimates that treatment would achieve common thresholds of cost-effectiveness if priced between $3,100 and $3,700...
tinyurl.com
September 8, 2025 at 8:14 PM
Institute for Clinical and Economic Review Publishes Evidence Report on Treatment for Non-Cystic Fibrosis Bronchiectasis: tinyurl.com/39by2hs5